Literature DB >> 1574772

[MR tomography and MR angiography--a new method for the planning of the irradiation of large abdominal fields].

A Köster1, B Kimmig, M Müller-Schimpfle, G Brix, W Semmler, M Wannenmacher.   

Abstract

Subdiaphragmatic radiation therapy in malignant lymphoma requires complete irradiation of retroperitoneal lymph nodes, spleen and splenic pedicle and optimal shielding of radiosensitive structures. The aim of our study was to develop a new method for individual field definition by using MR tomography and MR angiography. In 38 patients with malignant lymphoma coronal MR tomograms and MR angiograms of the abdominal vessels were obtained and superimposed by a specially created computer program. By using a Subtraskop the MRT/MRA superposition was geometrically projected onto the simulation film in correct scale. The target volume could individually be defined and was compared to standard treatment planning according to the definition by Abbatucci. In all patients an exact irradiation of the spleen, the splenic pedicle and prominent lymphatic masses was possible. Furthermore, this resulted in a 32% reduction of treated kidney volume in the average of patients. Noninvasiveness, acceptable costs and high accuracy support the application of this new method in clinical routine.

Entities:  

Mesh:

Year:  1992        PMID: 1574772

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  3 in total

1.  [Radiation effects in the left kidney after irradiation of the spleen].

Authors:  S Köst; K Keinert; G Endert; F H Glaser
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

2.  [A simple method for transposing MRI information to simulation films. Technical note].

Authors:  W Wagner; K Ostkamp; U Niewöhner-Desbordes
Journal:  Strahlenther Onkol       Date:  2000-05       Impact factor: 3.621

3.  [MRI simulation of bronchogenic carcinomas using an open low-field MRI].

Authors:  R Krempien; K Schubert; D Latz; F Wenz; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.